CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.35
+7.80%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.27
From 52W high−65.19%
Volume5.35M
Market cap$512.06M
P/E (TTM)—
P/S (TTM)28.0x
Div yield—
Key dataNov 4, 2026
Open
$2.27
From 52W high
−65.19%
Volume
5.35M
Market cap
$512.06M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
P/E (TTM)
—
RSI (14)
41.1
MomentumView details →
1D Return
+7.80%
YTD Return
−47.07%
SummaryUpdated Jun 1, 2026
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is an oncology-focused biopharmaceutical company founded in 2008 and headquartered in South San Francisco, California. The company went public in October 2015 and has developed a proprietary technology platform called Probody therapeutics for creating conditionally activated cancer treatments. CytomX operates primarily as a research and development organization, advancing both internal drug candidates and partnered programs with major pharmaceutical companies including Bristol-Myers Squibb, Amgen, Astellas, and others.
Similar companies
Latest newsMore news →
CytomX Therapeutics, Inc. announced that it will report its third-quarter 2026 financial results after the close of U.S. markets on November 5, 2026.6d agoCytomX Therapeutics reported a Q2 2026 loss of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.11, compared to break-even earnings per share a year ago.90d ago